09/16/2015

Abingdon Health Ltd.

Australian distributor appointed for myeloma rapid diagnostic

Seralite® – FLC and ADxLR3® reader

Abingdon Health Appoints Helena Laboratories (Australia) Pty. Ltd. As Exclusive Distributor For Australia & New Zealand


Abingdon Health Ltd, is pleased to announce that it has appointed Helena Laboratories (Australia) Pty. Ltd. (“Helena”) as exclusive distributor for Australia & New Zealand for the Seralite® – FLC rapid diagnostic test.


Seralite® – FLC is a rapid diagnostic device for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum as an aid to the diagnosis and management of multiple myeloma. The assay provides an accurate picture of disease status in 10 minutes. The simple to use, portable, rapid test allows the monitoring of patients in “real time” supporting faster decision making. By obtaining results rapidly, clinicians are able to better understand disease status and can make informed treatment decisions quickly and efficiently.


Helena has been a leading distributor of in vitro diagnostics in Australia and New Zealand for the past 30 years and is a fully owned subsidiary of Helena Laboratories Corp. Beaumont, Texas, a Group focused on the design, manufacture and support of Clinical Electrophoresis and Haemostasis systems.


To read the full press release please visit www.abingdonhealth.com/australian-distributor-appointed-for-myeloma-rapid-diagnostic/